Significant and Various Effects of ML329-Induced MITF Suppression in the Melanoma Cell Line.

ML329 (low-molecular MITF-specific inhibitor) cell viability malignant melanoma (MM) metabolic functions microphthalmia-associated transcription factor (MITF) three-dimensional spheroid culture

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Jan 2024
Historique:
received: 06 12 2023
revised: 20 12 2023
accepted: 04 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

To study the inhibitory effects on microphthalmia-associated transcription factor (MITF)-related biological aspects in malignant melanomas (MMs) in the presence or absence of the low-molecular MITF specific inhibitor ML329, cell viability, cellular metabolic functions, and three-dimensional (3D) spheroid formation efficacy were compared among MM cell lines including SK-mel-24, A375, dabrafenib- and trametinib-resistant A375 (A375DT), and WM266-4. Upon exposure to 2 or 10 μM of ML329, cell viability was significantly decreased in WM266-4, SK-mel-24, and A375DT cells, but not A375 cells, in a dose-dependent manner, and these toxic effects of ML329 were most evident in WM266-4 cells. Extracellular flux assays conducted using a Seahorse bioanalyzer revealed that treatment with ML329 increased basal respiration, ATP-linked respiration, proton leakage, and non-mitochondrial respiration in WM266-4 cells and decreased glycolytic function in SK-mel-24 cells, whereas there were no marked effects of ML329 on A375 and A375DT cells. A glycolytic stress assay under conditions of high glucose concentrations also demonstrated that the inhibitory effect of ML329 on the glycolytic function of WM266-4 cells was dose-dependent. In addition, ML329 significantly decreased 3D-spheroid-forming ability, though the effects of ML329 were variable among the MM cell lines. Furthermore, the mRNA expression levels of selected genes, including

Identifiants

pubmed: 38254754
pii: cancers16020263
doi: 10.3390/cancers16020263
pii:
doi:

Types de publication

Journal Article

Langues

eng

Auteurs

Nami Nishikiori (N)

Department of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Megumi Watanabe (M)

Department of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Tatsuya Sato (T)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.
Department of Cellular Physiology and Signal Transduction, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Masato Furuhashi (M)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Masae Okura (M)

Department of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Tokimasa Hida (T)

Department of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Hisashi Uhara (H)

Department of Dermatology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Hiroshi Ohguro (H)

Department of Ophthalmology, Sapporo Medical University, S1W17, Chuo-ku, Spporo 060-8556, Japan.

Classifications MeSH